MRI in Staging Ovarian Cancer Using MRI Contrast Agent

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00463996
Recruitment Status : Unknown
Verified April 2007 by University of Aarhus.
Recruitment status was:  Not yet recruiting
First Posted : April 20, 2007
Last Update Posted : April 20, 2007
Information provided by:
University of Aarhus

Brief Summary:
Can MRI be used to stage ovarian cancer?

Condition or disease
Ovarian Cancer

Detailed Description:
Staging of ovarian cancer can best be performed with CT or MRI compared to ultrasound. Studies have shown an increase in pos. predictive value by adding contrast i.v. to the MR-examination protocol. We compare staging of ovarian cancer by 1.MRI without contrast (standard method) to 2.MRI with contrast agent i.v. (new method)in the same patient. Golden standard are findings at operation.

Study Type : Observational
Enrollment : 50 participants
Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Værdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie
Study Start Date : April 2007
Estimated Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspicion of ovarian cancer

Exclusion Criteria:

  • recurrence of disease
  • contraindication to MRI, contrast agent
  • inoperable patients for other reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00463996

Contact: Liselotte Ibsen, doc +4589495201
Contact: Erik Lundorf, consultant +4589495251

Sponsors and Collaborators
University of Aarhus
Principal Investigator: Liselotte Ibsen, doc Aarhus University Hospital, BDA, Skejby Identifier: NCT00463996     History of Changes
Other Study ID Numbers: MR-Center-001
First Posted: April 20, 2007    Key Record Dates
Last Update Posted: April 20, 2007
Last Verified: April 2007

Keywords provided by University of Aarhus:
Ovarian cancer
Contrast agent

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders